Spimaco launches drug factory for cancer diseases and highly toxic drugs, in partnership with AstraZeneca, at SR272 mln

“The Saudi Pharmaceutical Industries and Medical Appliances Company – SPIMACO ADDWAEIH, announced on Thursday the inauguration of its new factory for Oncology and high potent drugs, with a total cost of SR272 million, built on an area of 2,800 square meters within SPIMACO ADDWAEIH Qassim Factory.
Wherein, the manufacturing agreements with multinational and biopharmaceutical manufacturers will be executed to manufacture high-level medicines to treat patients suffering from cancer.
The site, the first of its kind in Saudi, includes manufacturing & packaging areas, a full-quality organization, supported by state-of-the-art utilities in compliance with international standards required for the manufacturing of Oncology and highly potent drugs. The infrastructure work for the first phase began in 2017, and the construction of the manufacturing facility was completed in March 2021. All mandatory technical validation and safety measures were successfully completed, and Saudi Food and Drug Authority (SFDA) approval has been obtained regarding its operation.
However, the plant will start its commercial production only after the approval of the validation batches by the Saudi Food and Drug Authority (SFDA) which are currently in process.
The annual production capacity of the new factory is more than 275 million therapeutic units, uses the latest technologies, and applies the best standards in the field of pharmaceutical production, which ensures efficiency, smooth production, and safety of living beings and the environment.
SPIMACO ADDWAEIH is a major player in the Saudi pharmaceutical sector, along with its subsidiaries in 16 countries, provides reliable, high-quality pharmaceutical products and medical preparations that improve the healthcare sector, meet aspirations and expectations within the Kingdom and in all countries where it exists.”
This comes further to the announcement of the Saudi Company for Pharmaceutical Industries and Medical Supplies (SPIMACO ADDWAEIH), which was published on the Tadawul website on 3/8/2018, regarding the signing of a memorandum of understanding with (AstraZeneca) for the purpose of investment, technology transfer and manufacturing of a group of pharmaceutical preparations.